

10/765067

Form PTO-1449		ATTY DOCKET NO. 2801-0208P	APPLICATION NO. NEW-Rule 53(b) Div. of 10/145,712
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <small>(Use several sheets if necessary)</small>		APPLICANT Martin J. PAGE et al.	
		FILING DATE January 28, 2004	GROUP Unassigned 1644

**U.S. PATENT DOCUMENTS**

Examiner Initials	ID	Document Number	Year	Name	Class	SubClass	Filing Date
		USP 5605689	1997	Ammann			
		USP 4399216	1983	Axel et al.			
		USP 4456748	1984	Goeddel			
		USP 4816567	1989	Cabilly et al.			
		USP 5081235	1992	Shively et al.			
		USP 5098833	1992	Lasky et al.			
		USP 5116964	1992	Capon et al.			
		USP 5225538	1993	Capon et al.			
		USP 5336603	1994	Capon et al.			
		USP 5428130	1995	Capon et al.			
		USP 5455165	1995	Capon et al.			
		USP 5514582	1996	Capon et al.			
		USP 5460811	1995	Goeddel et al.			
		USP 5500362	1996	Robinson et al.			
		USP 5545403	1996	Page et al.			
		USP 5545404	1996	Page			
		USP 5545405	1996	Page			
		USP 5721108	1998	Robinson et al.			
		USP 5876961	1999	Crowe et al.			
		USP 5877293	1999	Adair et al.			
		USP 5985279	1999	Waldmann et al.			
		USP 6120767	2000	Robinson et al.			
		USP 5089397	1992	Kushner et al.			
		USP 5219996	1993	Bodmer et al.			
		USP 6020153	2000	Hardman et al.			
		USP 6010902	2000	Ledbetter et al.			
		USP 5,846,534	1998	Waldmann et al.			
		USP 6,331,415	2001	Cabilly et al.			
		USP 5,417,970	1995	Roskam et al.			

Examiner

Pheesix Gembel  
11/27/06

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

10/765067

**Examiner**

Phenyl (1m)<sup>2</sup> 11L-4106

**Date Considered**

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

10/768067

Form PTO-1449	ATTY DOCKET NO. 2801-0208P	APPLICATION NO. NEW-Rule 53(b) Div. of 10/145,712
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (Use several sheets if necessary)	APPLICANT Martin J. PAGE et al.	
	FILING DATE January 28, 2004	GROUP Unassigned <i>(644)</i>

**OTHER DOCUMENTS** (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.)

<i>PL</i>	Ashford et al., 1993, J. Biol. Chem. 268(5):3260-3267
	Baker et al., 1991, Antibodies, Immunoconjugates and Radiopharmaceuticals, 4:799-809.
	Beatty et al., 1989, Cancer Res. 49:1587-1594.
	Beatty et al., 1990, Cancer Res. 50:922s-926s.
	Benjamin et al., 1986, Nature 320:449-451.
	Bindon et al., 1985, Transplant. 40(5):538-544
	Bruggemann et al., 1987, J. Exp. Med. 166(5):1351-1361
	Byrn et al., 1990, Nature 344:667-670.
	Cabilly et al., 1984, PNAS USA 81(11):3273-3277
	Cabilly & Riggs, 1985, Gene 40(1):157-161.
	Cobbold, et al., pp.139-154, in Bone Marrow Purging and Processing and Processing, c.1990 by Alan R. Liss, Inc.
	Cobbold, 1991, Imm. Letters 29:117-122.
	Cobbold & Waldmann, 1984, Nature 308(5958):460-462.
	Cohen et al., 1972, PNAS USA 69(8):2110-2114.
	Colcher et al., 1989, Cancer Res. 49:1738-1745.
	Cosimi et al., 1990, Surgery 108(2):406-414.
	Crowe et al., 1992, Clin. Exp. Immunol. 87:105-110.
	Curti, 1993, Crit. Rev. in Oncol./Hematol. 14:29-39.
	Dall'Acqua & Carter, 1998, Curr. Op. In Biotech. 8:443-450.
	Davis et al., 1990, J. Biol. Chem. 265:10410-10418.
	Dillman, 1989, Ann. Int. Med. 111:592-600.
	DiMaggio J. et al., pp.177-203 in Cancer Chemo. & Biol. Resp. Mod. Vol. 11, J. Pinedo et al. (eds.) c. 1990 by Elsevier.
	De Waele et al., 1988, Eur. J. Biochem. 176:287-295.
	Duda et al., 1990, J. Surgical Onc. 44:73-77.
	Dyer et al., 1990, Blood 75:709-714.
	Dyer et al., 1990, Leukemia & Lymphoma 2:179-193.
<i>PL</i>	Ebert, 1991, Dissertation, University for Soil Cultivation in Vienna, Austria: 1-96.

Examiner

*Philip Stauder*  
11/27/06


Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

10/765067

Form PTO-1449		ATTY DOCKET NO. 2801-0208P	APPLICATION NO. NEW-Rule 53(b) Div. of 10/145,712
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <small>(Use several sheets if necessary)</small>		APPLICANT Martin J. PAGE et al.	
		FILING DATE January 28, 2004	GROUP Unassigned 1644
	Feys et al., 1988, Int. J. Cancer Suppl. 2:26-27.		
	Field et al., 1990, 10th Mtg Euro. Soc. For Ani. Cell Tech., Spier et al., Eds. Pp. 742-744.		
	Fukuda et al., 1989, Blood 73(1):84-89.		
	Geisse et al., 1996, Protein Exp & Pur. 8:271-282.		
	Gillies et al., 1989, Bio/Tech. 7:799-804.		
	Goeddel et al., 1979, Nature 281(5732):544-548.		
	Goeddel et al., 1980, Nuc. Acids Res. 8(18):4057-4074.		
	Goochée & Monica, 1990, Bio/Tech. 8:421-427.		
	Goochée et al., 1991, Bio/Tech. 9:1347-1355.		
	Gorman et al., 1991, PNAS 88:4181-4185.		
	Hale, 1983, Mol. Biol. Med. 1:321-334.		
	Hale, 1990, Excerpt from Progress Report - MRC Wellcome Ther. Antibody Centre.		
	Hale et al., 1985, Br. J. of Haematol. 60(1):41-48.		
	Hale et al., 1988, Lancet 2(8625):1394-1399.		
	Hale et al., 1990, Tissue Antigens 35:118-127.		
	Harabayashi et al., 1991, Mitsubishi Kasei R&D Rev. 5(1):85-91.		
	Harris et al., 1990, Proc. 34 <sup>th</sup> Ohalo Conf, Eilat, Israel pgs. 465-477.		
	Harris et al., 1993, TIBTECH 11:42-44.		
	Haynes, 1983, Nucl. Acids Res. 11:687-706.		
	Hird et al., pp.183-189 in Genes & Cancer, Carner & Sikora (eds.), c.1990 by J. Wiley & Sons.		
	Hutzell et al., 1991, Cancer Res. 51:181-189.		
	Joziasse et al., 1999, Subcell Biochem. 32:25-48.		
	Joziasse et al., Eur. J. Biochem., 267:6501-6508 (2000).		
	Kaetzel et al., 1985, PNAS USA 82:7280-7283.		
	Kaetzel et al., 1988, J. Biol. Chem. 263(13):6344-6351.		
Kagawa et al., 1988, J. Biol. Chem. 263(33):17508-17515.			
Kaufman et al., 1985, Mol. Cell. Biol. 5(7):1750-1759.			
Kaufman et al., 1990, Meth. Enzymol. 185:537-566.			
Kaufman et al., 1986, PNAS USA 83:3136-3140.			
Khazaeli, Meredith et al., 1990, Abstract Submission, "Pharmacokinetics of Single and Repeated Therapeutic...," 3 <sup>rd</sup> Ann. Conf. On Radioimmunodetection and Radioimmunotherapy of Cancer.			

Examiner


  
11/24/06

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

10/765067

Form PTO-1449		ATTY DOCKET NO. 2801-0208P	APPLICATION NO. NEW-Rule 53(b) Div. of 10/145,712
INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)		APPLICANT Martin J. PAGE et al.	
		FILING DATE January 28, 2004	GROUP Unassigned 1644
<p>PG</p> <p>Khazaeli, Plott et al., 1990, Abstract Submission, "Pharmacokinetics of Treatment Doses of Chimera I-131 B72.3 in Colorectal Carcinoma Patients"; 37<sup>th</sup> Ann. Mtg. Soc. Of Nuclear Med.</p> <p>Khazaeli et al., 1991, Cancer Res. 51:5461-5466.</p> <p>Khazaeli et al., "Frequent Anti-V Region Immune Response to Mouse B72.3 Monoclonal Antibody", J. Clin. Immunol. (submitted)</p> <p>Klein et al., 1981, PNAS USA 78(1):524-528.</p> <p>Kuzel et al., 1990, Oncol. 4(3):77-84, 89.</p> <p>Kyle et al., 1989, Ann. Rheum Dis 48(5):428-429, (Abstract).</p> <p>Leatherbarrow et al., 1985, Mol. Immunol. 22(4):407-415.</p> <p>Lifely et al., 1995, Glycobiol. 5(3):813-822.</p> <p>Lim et al., 1993, Lancet 341:432-433.</p> <p>LoBuglio et al., Abstract Submission, 3<sup>rd</sup> Conf. On Radiodetection and Radioimmunotherapy of Cancer, "Human Immune Response to Chimeric B72.3(γ4)".</p> <p>LoBuglio &amp; Saleh, 1992, Am. J. Med. Sci. 304(3):214-224.</p> <p>LoBuglio et al., 1989, PNAS USA 86:4220-4224.</p> <p>LoBuglio et al., pp.291-295 in Advances in the Applications of Monoclonal Antibodies in Clinical Oncology, Chapman &amp; Hall (eds.), c. 1991.</p> <p>LoBuglio et al., 1992, Abstract Submission, ASCO Annual Meeting, "Dose Fractionation Trial of <sup>131</sup>I-Chimera B72.3 In Patients With Metastatic Colon Cancer".</p> <p>LoBuglio et al., 2000, Deposition in Interference 104,532.</p> <p>Lockwood et al., 1993, Lancet 341:1620-1622.</p> <p>Lyons et al., 1990, Protein Eng. 3(8):703-708,</p> <p>Martz, 1998, BancBoston Analyst Report, Healthcare Res. Pgs. 69-86.</p> <p>Mathieson et al., 1990, New England J. of Med. 323(4):250-254,</p> <p>Meredith et al., 1990, Abstract Submission 5<sup>th</sup> Congress of World Federation of Nuclear Biology and Medicine, "Diagnostic and Therapeutic Doses of Radiolabeled Mouse/Human Chimeric Monoclonal Antibodies".</p> <p>Meredith et al., 1990, Abstract Submission, 3<sup>rd</sup> Annual Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, "Phase I Trial of <sup>131</sup>I-Chimeric Mouse/Human B72.3 (Anti-Tag-72) in Patients with Metastatic Colon Cancer".</p> <p>Meredith et al., 1990, Abstract Submission, Soc. Nucl. Med. 37<sup>th</sup> Ann. Meeting, "Body Distribution of Two I-131-Labeled Chimeric Monoclonal Antibodies".</p> <p>Meredith et al., 1991, J. Nuc. Med. 32(6):1162-1168.</p> <p>Meredith et al., 1992, J. Nuc. Med. 33(1):23-29.</p> <p>✓ Meredith, 1990, Protocol: UAC 180 NCI:T89-0144 (NCI/CTEP Sheets)</p>			

Examiner

P. Haupfambe 11/27/06

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

10/765067

Form PTO-1449		ATTY DOCKET NO. 2801-0208P	APPLICATION NO. NEW Rule 53(b) Div. of 10/145,712
INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)		APPLICANT Martin J. PAGE et al.	
		FILING DATE January 28, 2004	GROUP Unassigned 1644
Meredith et al., 1989, Protocol: UAC 180. Meredith et al., 1990, Protocol: UAC 180 (Amended) Meredith et al., 1995, J. Nuc. Med. 36:2229-2233. Meredith et al., Med. Physics "Dosimetry of Solid Tumors" (submitted) Mizouchi et al., 1988, Biochem. J. 254:599-603. Morrison et al., 1984, PNAS USA 81(21): 6851-6855. Morrison et al., 1988, Cancer Invest. 6(2):185-192. Morrison et al. , 1988, Clin. Chem. 34(9):1668-1675. Nadler et al., 1980, Cancer Res. 40:3147-3154. Nadler et al., 1980, J. Immunol. 125(2):570-577. Nakatani et al., 1989, Bio/Tech. 7:805-810. Neuberger et al., 1984, Nature 312(5995):604-608. Neuhaus et al., 1989, JACC 14:1566-1569. Neumaier et al., 1990, Cancer Res. 50:2128-2134. Nishimura Y et al., Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for common Actue Lymphocytic Leykemia Antigen", Database accession No. PREV198784006235 XP 002238118 (Abstract Only) Nose & Wigzell, 1983, PNAS USA 80:6632-6635. Oh-edo et al., 1990, J. Biol. Chem. 265(20):11432-11435. Osband et al., 1990, Immunol. Today 11(6):193-195. Page & Sydenham, 1991, Bio/Tech. 9:64-68. Paul, MD (Ed), 1993, "IgG Subclasses" Fundamental Immunol. 3rd Ed. Chap 22, pgs. 838-839. Peakman et al., 1994, Hum. Antibod. Hybrid. 5:65-74. Poynton et al., 1993, Lancet 341:1037. Primus et al., 1990, Cancer Immunol. & Immunother. 31:349-357. Rademacher et al., 1988, Ann. Rev. Biochem. 57:785-838. Raju et al., 1996, Biotechnol. Appl. Biochem. 24:191-194. Raju et al., 2000, Glycobiol. 10(5):477-486. Rhodes, 1988, Adv. Anim. Cell. Biol. Technol. Bioprocess 472-474. Rhodes & Birch, 1988, Bio/Tech. 6:518-523. Riechmann et al., 1988, J. Mol. Biol. 203(3):825-828. Riechmann et al., 1988, Nature 332(6162):323-327. Ringold et al., Journal of Molecular and Applied Genetics, Vol. 1, No. 3, pp.165-175 (1981)			

Examiner

Peter George 11/27/06

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

10/765067

Form PTO-1449		ATTY DOCKET NO. 2801-0208P	APPLICATION NO. <del>NEW-Rule 53(b) Div. of 10/145,712</del>
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <small>(Use several sheets if necessary)</small>		APPLICANT Martin J. PAGE et al.	
		FILING DATE January 28, 2004	GROUP Unassigned 1644
<p>Routledge et al., 1991, Eur. J. Immunol. 21:2717-2725.</p> <p>Ruker et al., 1991, Ann. NY Acad. Of Sci. Recom. DNA Tech. I 646:212-219.</p> <p>Schlom et al., 1980, PNAS USA 77(11):6841-6845.</p> <p>Seaver, 1994, Genetic Eng. News 14(14):10, 21.</p> <p>Sekigawa et al., 1990, J. Virology 64:5194-5198.</p> <p>Shively, Declaration of October 30, 2000</p> <p>Shively, Deposition Transcript Interference 104,532</p> <p>Smith et al., 1990, J. Biol. Chem. 265(11):6225-6234.</p> <p>Spellman et al., 1989, J. Biol. Chem. 264:14100-14111.</p> <p>Stevenson et al., 1989, Anti-Cancer Drug Des. 3:219-230.</p> <p>Stevenson et al., 1991, Blood 77:1071-1079.</p> <p>Takeuchi et al., 1988, J. Biol. Chem. 263:3657-3663.</p> <p>Urlab &amp; Chasin, 1980, PNAS USA 77:4216-4220.</p> <p>van Nagell et al., 1980, Cancer Res. 40(3):502-506.</p> <p>Vandamme et al., 1990, Eur. J. Biochem. 192:767-775.</p> <p>Waldmann, 1991, Science 252:1657-1662.</p> <p>Waldmann, 2000, Ann. Oncol. 11(Suppl. 1(3)):101-106.</p> <p>Waldmann &amp; Goldman, 1989, Am. J. Kidney Dis. 14(5)(Suppl. 2):45-53.</p> <p>Waldmann et al., 1984, Lancet 2(8401):483-486.</p> <p>Ward et al., 1991, Nature 352:434-436.</p> <p>Weidle et al., 1987, Gene 51(1):21-29.</p> <p>Weidle et al., 1987, Gene 60(2-3):205-216.</p> <p>Weikert et al., 1999, Nature Biotech. 17:1116-1121.</p> <p>Whittle et al., 1987, Protein Eng. 1(6):499-505.</p> <p>Wilhelm et al., 1990, Bio/Tech. 8:321-325.</p> <p>Williams et al., 1990, Cancer Res. 50 (suppl.):1029s-1030s.</p> <p>Wood et al., 1990, J. Immunol. 145(9):3011-3016.</p> <p>Yarrenton, 2000, Deposition in Interference 104,532.</p> <p>Zettlmeisl et al., 1987, Bio/Tech. 5:720-725.</p> <p>Activase (Alteplase) package insert</p> <p>1990, Status Report: Phase I Contract (NO1-CM-97611) CTEP.</p> <p>1991, Status Report Phase I Contract (NO1-CM-97611) CTEP.</p>			

Form PTO-1449

ATTY DOCKET NO.

APPLICATION NO.

Examiner

PAMELA GRANDE  
11/17/06

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

10/765067

INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	2801-0208P	NEW Rule 53(b) Div. of 10/145,712
	APPLICANT Martin J. PAGE et al.	
	FILING DATE January 28, 2004	GROUP Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)


1992, Status Report Phase I Contract (NO1-CM-97611) CTEP.
Jury Verdict from Civil Action No. 99-335 (RRM), Glaxo Wellcome, Inc. v. Genentech, Inc. (2001)
Ashwell & Harford, 1982, <i>Ann. Rev. Biochem.</i> 51:531-554.
Boyd et al., 1995, <i>Mol. Immunol.</i> 32(17/18):1311-1318.
Carr et al., 1989, <i>J. of Biol. Chem.</i> 264(35):21286-21295.
Conradt et al., 1987, <i>J. of Biol. Chem.</i> 262(30):14600-14605.
Fujii et al., 1990, <i>J. of Biol. Chem.</i> 265(11):6009-6018.
Jefferis & Lund, 1997, <i>Chem. Immunol.</i> 65:111-128.
Kornfeld et al., 1971, <i>J. of Biol. Chem.</i> (10):3259-3268.
Mattu et al., 1998, <i>J. of Biol. Chem.</i> 273(4):2260-2272.
Parekh et al., 1985, <i>Nature</i> 316:452-457.
Parekh et al., 1989, <i>Biochem.</i> 28:7644-7662.
Parekh et al., 1989, <i>Biochem.</i> 28:7670-7679.
Rademacher et al., 1983, <i>Biol. Soc. Transactions</i> (11)2:132-134.
Rothman et al., 1989, <i>Mol. Immunol.</i> 26(12):1113-1123.
Sasaki et al., 1987, <i>J. of Biol. Chem.</i> 262(25):12059-12076.
Sutton & Phillips, 1983, <i>Biol. Soc. Transactions</i> (11)2:130-132.
Written Questioning in JP 333868/91 with Translation and Comments

Examiner

Paul Grunberg  
11/17/06

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/765,067-Conf.#2323
				Filing Date	January 28, 2004
				First Named Inventor	Martin J. PAGE
				Art Unit	1644
				Examiner Name	P. Gabel
Sheet	1	of	5	Attorney Docket Number	2801-0208P

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
AA*	US-5,807,715	09-15-1998	Morrison et al.		
AB*	US-5,876,961	03-02-1999	Crowe et al.		
AC*	US-5,122,469	06-16-1992	Mather et al.		
AD*	US-5,633,162	05-27-1997	Keen et al.		
AE*	US-5,316,938	05-31-1994	Keen et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> + Number-Kind Code <sup>4</sup> (if known)			
BA	WO-91/04336-A1		04-04-1991	Centocor, Inc.	
BB	WO-87/01131-A1		02-26-1987	Gene Labs, Inc.	
BC	WO-93/02108		02-04-1993	IDEC Pharm. Corp.	
BD	WO-89/00999-A1		02-09-1989	Inter Genetics Eng., Inc.	
BE	EP-0 404 003		12-27-1990	XOMA Corp.	
BF	EP-0 314 161-A1		05-03-1989	Bristol Myers Squibb	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. \*Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
CA	Reply of Applicant concerning EP92306420.8 dated 15 October 1999.				
CB	Liu et al.; Gene 54, pp. 33-40 (1987)				
CC	Signed Declaration of Dr. John Adair, from EP 92 06420.8				
CD	Neuberger M.S. et al.; Nucleic Acid Research, Vol. 16, No. 14, pp. 6713-6724 (1988)				
CE	Rose B. et al.; Molecular Immunology, Vol. 29, No. 1, pp. 131-144 (1992).				
CF	Declaration of Dr. J. Adair (unsigned), from EP 92 306 420.8				
CG	Levy, S. et al.; Gene 54, pp. 167-173 (1987)				
CH	Persson M.A. et al.; PNAS, Vol. 88, pp. 2432-2436 (March 1991).				
CI	Liu, A. Y. et al.; J. Immunology, Vol. 139, No. 10, pp. 3021-3528 (November 1987).				
CJ	Liu, A.Y. et al.; PNAS, Vol. 84, pp. 3439-3443 (1987).				
CK	Mountain A and Adair J.R.; Biotechnology and Genetic Engineering Reviews, Vol. 10, p. 1-142 (December 1992).				
CL	Sambrook et al.; Molecular cloning: A Laboratory Manual, pp. 8.8-8.10. (1989)				
CM	Lewis, A. P. et al.; Hum. Antibod. Hybridomas, Vol. 3, pp. 146-152 (July 1992).				
CN	Ehrlich, P.H. et al.; Molecular Immunology, Vol. 28, No. 4/5, pp. 319-322 (1991).				
CO	Reply of Applicant concerning EP92306420.8 dated 28 May 1998 (as filed in Opposition).				
CP	Knight, D.M. et al.; Hum. Antibod. Hybridomas, Vol. 3, pp. 129-136 (July 1992).				
CQ	Robinson B.R. et al.; Hum. Antibod. Hybridomas, Vol. 2, pp. 84-93 (April 1991).				

Examiner Signature	Date Considered
Birch, Stewart, Kolasch & Birch, LLP	MAA:bmp

Patent Major 11/27/06



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/765,067-Conf.#2323
				Filing Date	January 28, 2004
				First Named Inventor	Martin J. PAGE
				Art Unit	1644
				Examiner Name	P. Gabel
Sheet	2	of	5	Attorney Docket Number	2801-0208P

	CR	Bebbington C.R.; Methods; A companion to Methods in Enzymology; Vol. 2, No. 2, pp. 136-145 (April 1991).	
	CS	Carter, P. et al.; PNAS, Vol. 89, pp. 4285-4289 (May 1992)	
	CT	Handa-Corriigan et al., Enzymol. Microb. 11: 230-235 (1989)	
	CU	Schneider et al., J. Immunol. Meth. 116: 65-77 (1989)	
	CV	Ehrlich et al.; Hum. Antib. Hybridomas, Vol. 1, pp. 23-26 (1990)	
	CW	Bebbington, C.R. et al.; Biotechnology, Vol. 10, pp. 169-175 (1992)	
	CX	Fouser, L.A. et al.; Biotechnology, Vol. 10, pp. 1121-1127 (1992)	
	CY	Gillies, S.D. et al.; J. Immunol. Methods, Vol. 125, pp. 191-202 (1989)	
	CZ	King, D.J. et al.; Biochem. J., Vol. 281, pp. 317-323 (1992)	
	CA1	Lafick, J. W. et al.; Biotechnology, Vol. 7, pp. 934-938 (1989).	
	CB1	Newman, R. et al.; Biotechnology, Vol. 10, pp. 1455-1460 (1992)	
	CD1	Specification of U.S. Appln. No. 07/856,281.	
	CE1	Reasons for Allowance in U.S. Patent 5,876,961 (App. No. 08/378,939).	
	CF1	Oka et al., Bioprocess Technol. Vol. 10, 71-92 (1990)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

*P. Gabel (Signature)  
11/27/06*

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/145,992-Conf. #93992323
				Filing Date	January 28, 2004
				First Named Inventor	Martin J. PAGE
				Art Unit	1644
				Examiner Name	P. Gabel
Sheet	3	of	5	Attorney Docket Number	2801-0174P

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PS	AA*	US-4,205,126	05-27-1980	Cartaya, Oscar A.	
	AB*	US-4,608,337	08-26-1986	Croce, Carlo M.	
	AC*	US-4,657,866	04-14-1987	Kumar, S.	
	AD*	US-4,767,704	08-30-1988	Cleveland, W. L. et al.	
	AE*	US-4,929,706	05-29-1990	Heifetz, A.H. et al.	
	AF*	US-5,001,065	03-19-1991	Lerrick, J.W. et al.	
	AG*	US-5,045,468	09-03-1991	Darfler, F.J.	
	AH*	US-5,063,157-A	11-05-1991	Stockinger, H.	
	AI*	US-5,135,866	08-04-1992	Heifetz, A. H. et al.	
W	AJ*	US-6,291,158-B1	09-18-2001	Winter, G. P. et al.	


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA**	JP-63-7780-A	01-13-1988	Nippon Zemiyaku Industries, Co., Ltd.	✓
	BB	FR-2 543 158-A1	09-28-1984	Institut National de la Sante et de la Recherche Medicale	✓
	BC	JP-01 23460-A	04-02-1986	Nissui Seiyaku Co.	✓
W	BD	EP-0 307 247-A2	03-15-1989	Genentech, Inc.	✓
M	BE	EP-0 316 058-A1	05-17-1989	Collaborative Research, Inc.	✓
V	BF**	EP-0 239 400-A2	09-30-1987	Winter, Gregory Paul	✓
	BG	EP-0 325 190-A2	11-05-1991	BOEHRINGER MANNHEIM GmbH	✓
	BH	EP-0 389 786-A1	10-03-1990	W. R. Grace & Co.-Conn.	✓
	BI	EP-0 390 327-A2	10-03-1990	Eli Lilly and Company	✓
A	BJ	WO-88 00967-A1	02-11-1988	The University of New South Wales (AU)	✓
	BK	GB-2 196 328-A1	04-27-1988	Ceskoslovenska Akademie Ved	✓
					✓
					✓
					✓
					✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>P. Gabel</i>	Date Considered
--------------------	-----------------	-----------------

Birch, Stewart, Kolasch & Birch, LLP

MAA:bmp



Substitute for form 1449A/B/PTO

**Complete if Known**

Application Number	10/145,992-Conf. #93992323
Filing Date	January 28, 2004
First Named Inventor	Martin J. PAGE
Art Unit	1644
Examiner Name	P. Gabel

Sheet

4

of

5


Attorney Docket Number 2801-0174P

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CA	1990 GIBCO BRL Catalogue & Reference Guide		
CB	Ahmed, S., "Eating Human Hair by Another Name?" (2001) [www.albalagh.net/halal/col2.shtml]		
CC	Blech, Z. Y., reprinted with permission from <i>MK News and Views</i> , Vol. IV, Issue 6 (May 2003)		
CD	Brown, P. et al., <i>Emerging Infectious Diseases</i> , Vol. 7, No. 1, pp. 6-16 (2001)		
CE	C6852, <i>Biochemicals and Reagents for Life Science Research</i> , p. 600 (2002-2003) Sigma-Aldrich Company (Current website information also included)		
CF	C7880, <i>Biochemicals and Reagents for Life Science Research</i> , p. 600 (2002-2003) Sigma-Aldrich Company (Current website information also included)		
CG	C8503, <i>Biochemicals and Reagents for Life Science Research</i> , p. 508 (2002-2003) Sigma-Aldrich Company (Current website information also included)		
CH	Darlier, F. J., <i>In Vitro Cell Dev. Biol.</i> , Vol. 26, pp. 779-783 (August 1990).		
CI	Darlier, F. J.; <i>In Vitro Cell. Dev. Biol.</i> , Vol. 26, pp. 769-778 (August 1990).		
CJ	Dickman, Steven, <i>Nature</i> , Vol. 329, , p. 193 (1987).		
CK	Freshney, R. I. et al.; <i>Culture of Animal Cells</i> , Second Edition, Wiley-Liss, pp. 57-84 (1987).		
CL	Dyer, Martin J.S. et al.; <i>Blood</i> , Vol. 73, No.6, pp. 1431-1439 (1989).		
CM	Goeddel, David V. et al.; <i>Proceedings of the National Academy of Sciences USA</i> , Vol. 76, No. 1, pp. 106-110 (1979)		
CN	Feldman G.M., (Oct. 2001). "Amino Acid Production and the Associated Theoretical Risk of BSE Transmission from their Use in the Production of Biologicals, Drugs, and Medical Devices", <i>FDA TSA Advisory Committee Meeting</i> [www.fda.gov/ohrms/dockets/ac/01/slides/		
CO	Feys, V. et al.; <i>Chemical Abstracts</i> , Vol. 108, (23) p. 514 (1988). Abs. No. 202886C		
CP	Gasser, F. et al.; <i>In Vitro Cellular &amp; Developmental Biology</i> , Vol. 21, No. 10, pp. 588-592 (1985).		
CQ	Hale, G. et al.; <i>Journal of Immunological Methods</i> , Vol. 103, pp. 59-67 (1987).		
CR	Hale, G. et al.; <i>Mol. Biol. Med.</i> , Vol. 1, pp. 305-319 (1983).		
CS	Ham, R. G. <i>Proceedings of the National Academy of Sciences</i> , Vol. 53, pp. 288-293 (1965)		
CT	Hamilton, W. G. et al.; <i>In Vitro</i> , Vol. 13, No. 9, pp. 537-547 (1977).		
CU	Holter, E. et al.; <i>Biochimica et Biophysica Acta</i> , Vol. 721, pp. 321-327 (1982).		
CV	Kagawa, Y. et al.; <i>Journal of Biochemistry</i> , Vol. 68, pp. 133-136 (1970).		
CW	Keay, L.; <i>Biotechnology and Bioengineering</i> , Vol. XVIII, pp. 363-382 (1976).		
CX	Kohrle, J.; <i>Biochimie</i> , Vol. 81, pp. 527-533 (1998).		
CY	Marquis, C.P. et al.; <i>Cytotechnology</i> , Vol. 2, pp. 163-170 (1989).		
CZ	McCormick, F. et al.; <i>Molecular and Cellular Biology</i> , Vol. 4, pp. 166-172 (1984).		
CC1	McKeehan W. L. et al., <i>Proceedings of the National Academy of Sciences, USA</i> , Vol. 73, No. 6, pp. 2023-2027 (1976).		

7/16/06  
11/27/06

Examiner Signature	Date Considered
Birch, Stewart, Kolasch & Birch, LLP	MAA:bmP



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/145,992-Conf. #93992323
				Filing Date	January 28, 2004
				First Named Inventor	Martin J. PAGE
				Art Unit	1644
				Examiner Name	P. Gabel
Sheet	5	of	5	Attorney Docket Number	2801-0174P

CD1	Mendiaz, E. et al.; <i>In Vitro Cellular &amp; Developmental Biology</i> , Vol. 22, pp. 66-74 (1986)
CE1	Murphy, <i>Science</i> , Vol. 273 pp. 746-747 (1996)
CF1	Nakamori, S. et al.; <i>Applied and Environmental microbiology</i> , Vol. 64, No. 5, pp. 1607-1611 (1998).
CG1	Ogata, M. et al.; <i>Applied Microbiology Biotechnology</i> , Vol. 38, No. 4, pp. 520-525 (1993).
CH1	Phillipotts, R.J., <i>Cytotechnology</i> , Vol. 2, pp. 161-162 (1989).
CI1	Rabbi S. Emanuel, MK Vaad Hair, Vol. IV, Issue 7, 9 pages (2003) [www.mk.ca/page611.php]
CJ1	Regenstein et al.; E-Journal [www.Kashrut.com], Kosher Issues for Today's Dairy Industry, 2002
CK1	Saban, Tahir "Food Additives from Islamic Perspective", Version 1.3 (2004) [www.rsv1.mycity/at/privat.9704236/lm/LM-en.html]
CL1	Salahuddin, S. Z. et al.; <i>Journal of Experimental Medicine</i> , Vol. 155, pp. 1842-1857 (1982).
CM1	Scahill, S. J. et al.; <i>Proceedings of the National Academy of Sciences</i> , Vol. 80, pp. 4654-4658 (1983).
CN1	Sano, Emiko et al.; <i>Cell Structure and Function</i> , Vol. 13, pp. 143-159 (1988)
CO1	Katsuta and Takaoka, <i>Japanese Journal of Experimental Medicine</i> , Vol. 30, No. 3, pp. 235-259 (1960).
CP1	Higuchi, Kioshi; <i>Advances in Applied Microbiology</i> , Vol. 16, pp. 111-136 (1973).
CQ1	Abstract of USPTO database regarding TM for NUCELLIN of Eli Lilly (2000)
CR1	Organic. Chem., John Wiley & Sons, Vol. II, 2 <sup>nd</sup> ed. (1943), pp. 1129-1130, 1136-1137
CS1	Schneider, Y-J., J. Immunol. Meth. 116, pp. 65-77 (1989)
CT1	Taylor et al., <i>Mutation Research</i> , Vol. 67, pp. 65-80 (1979)
CU1	Whitaker et al., <i>Biopharm.</i> Vol. 3 (8), pp. 5-6 (1990)
CV1	Spira et al., <i>Trends in Animal Cell Cultures Tech.</i> , pp. 67-73 (1990)
CW1	Titeux et al., <i>J. Cell. Physiol.</i> , Vol. 121, pp. 251-256 (1984)
CX1	Tsujimoto et al., <i>J. Biochem.</i> , Vol. 106, pp. 23-28 (1989)
CY1	Yang et al., <i>PNAS</i> , Vol. 81, pp. 2752-2759 (1984)
CZ1	Zekauskas et al., <i>J. Okla. State Med. Assoc.</i> , Vol. 83, pp. 447-448 (1990)
CA2	Iscove & Melchers, <i>J. Exper. Med.</i> , Vol. 147, pp. 925-933 (1978)
CB2	Dulbecco & Freeman, <i>Virology</i> , Vol. 8, pp. 396-397 (1959)
CC2	Eagle H., <i>Science</i> , Vol. 130, pp. 432-437 (1959)
CD2	Sigma-Aldrich Company Search Results regarding Trypsin (2004)
CE2	Hale et al., <i>Transplantation</i> , Vol. 45, pp. 753-759 (1988)
CF2	Katsuta et al., <i>Meth. in Cell Biol.</i> , Vol. 6, pp. 1-42 (1973)
CG2	Noda, <i>Chem. Abstracts</i> , 110, page 652, Abstract No. 171821n (1989)
CH2	I5500 Biochemicals & Reagents for Life, page 1147 (2002-2003), Sigma-Aldrich Company
CI2	Loren, K., <i>Vibrant Life</i> , Vol. 2, 13 pages (1999)
CJ2	Ungemach et al., 50 <sup>th</sup> Meeting of Joing FAO/WHO Expert Committee on Food Additives (JECFA), WHO, 1998
CK2	Schneider & Levoix, <i>J. Immunol. Meth.</i> , Vol. 129, pp. 251-268 (1990)
CL2	Luff P. cited in "The BSE Inquiry: The Report by the British Government (2000)
CM2	Merten et al., <i>Production of Biologicals from Animal Cells in Culture Research, Development, and Achievements</i> , 10 <sup>th</sup> Mtg., Avignon, France (1990) pp. 170-179 and 352-360

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
-----------------------	--------------------

Birch, Stewart, Kolasch & Birch, LLP

MAA:bmp

Plants 61 m62  
11/23/04



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/765,067-Conf.#2323
(Use as many sheets as necessary)				Filing Date	January 28, 2004
				First Named Inventor	Martin J. Page
				Art Unit	1644
				Examiner Name	P. Gambel
Sheet	1	of	2	Attorney Docket Number	2801-0208P

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
✓	CA	Opposition against EP 1247865 filed by Cambridge Antibody Technology Limited, (UK) on February 2, 2006.
✓	CB	Opposition against EP 1 247 865 filed by Amgen Inc., (USA) on March 15, 2006.
✓	CC	Opposition against EP 1 247 865 filed by ASTRAZENECA AB, (Sweden) on March 13, 2006.
✓	CD	Opposition against EP 1 247 865 filed by Schering, AG (Germany) on March 13, 2006.
✓	CE	Opposition against EP 1 247 865 filed by Serono International S.A. (Switzerland) on February 27, 2006.
✓	CF	Opposition against EP 1 247 865 filed by Biovitrum AB (Sweden) on March 15, 2006.
✓	CG	Opposition against EP 1 247 865 filed by Biol invent International AB (Sweden) on March 15, 2006.
✓	CH	Opposition against EP 1 247 865 filed by Genentech Inc. (USA) on March 15, 2006.
✓	CI	Opposition against EP 1 247 865 filed by Boehringer Ingelheim Pharma GmbH & Co., KG (Germany) on March 15, 2006.
✓	CJ	Opposition against EP 1 247 865 filed by Novartis AG (Switzerland) on March 15, 2006.
✓	CK	Opposition against EP 1 247 865 filed by ABBOTT LABORATORIES (USA) on March 15, 2006.
✓	CL	Opposition against EP 1 247 865 B1 filed by Wyeth (USA) on March 15, 2006.
✓	CM	Opposition against EP 1 247 865 filed by GENMAB A/S (Denmark) on March 15, 2006.

*Martin J. Page* 11/27/06

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/765,067-Conf.#2323
				Filing Date	January 28, 2004
				First Named Inventor	Martin J. Page
				Art Unit	1644
				Examiner Name	P. Gambel
Sheet	2	of	2	Attorney Docket Number	2801-0208P

<i>M</i>	CN	Lerrick, J.W. et al.; Biochemical & Biophysical Research Communications, Vol. 160, No. 3 (1989), pp. 1250-1256.	
<i>M</i>	CO	Van Meurs, G.J.F. et al.; Journal of Immunological Methods, Vol. 95 (1986) pp. 123-128.	
<i>M</i>	CP	Teshima, G. et al.; Biochemistry, Vol. 30, (1991), pp. 3916-3922.	
<i>M</i>	CQ	DiAugustine, R.P. et al.; Analytical Biochemistry, Vol. 165 (1987), pp. 420-429.	
<i>M</i>	CR	Cini, J.K. et al.; Archives of Biochemistry and Biophysics; Vol. 263, No. 1, pp. 96-106(1988)	
<i>M</i>	CS	Wingfield, P. et al.; Eur. J. Biochem., Vol. 165, pp. 537-541 (1987)	
<i>M</i>	CT	Moellering et al., BioPharm. (February) 1990, pp. 33-38.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

*Martin Gambel 11/27/06*

Examiner Signature	Date Considered
--------------------	-----------------

\*Submitted with an English translation

GMM/MAA/CSB